CD274 and neoplasm: For example, in our analysis of nAlb-Cy5 biodistribution, we found ~ 11% ID/gram tumor in the EMT6 model and a comparable ~ 8.4% ID/gram tumor in B16.10 model (Fig. 2), yet a substantial difference in response to both nAlb-diABZI alone and in combination with anti-PD-L1 that may be attributed to the relatively low immunogenicity to B16.F10 tumors.